0ND5.LSE

H Lundbeck A/S

0ND5.LSE, UK

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

https://www.lundbeck.com

Stock Price

DKK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2022-03-31)

Health Score

Investors

* Institutions hold a combined 0.00% of the total shares of H Lundbeck A/S

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.16

Latest Release

Date

2022-03-31

EPS Actual

2.07

EPS Estimate

2.41

EPS Difference

-0.34

Surprise Percent

-14.1079%

Investing Fit Scorecard

(Last Updated 2022-03-31)

Deep Value
Weak Deep Value(0)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(1.5)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Low Quality Business(0)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2022-03-31)

Revenue

DKK 0

Cost Of Revenue

DKK 0

Gross Profit

DKK 0

Operating Expenses

DKK 0

Operating Income

DKK 0

Interest Expense

DKK 0

Pretax Income

DKK 0

Net Income

DKK 0

Income Tax Expense

DKK 0

EBITDA

DKK 0

Total Other Income Expense Net

DKK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2022-03-31)

Cash

DKK 0

Short Term Investments

DKK 0

Receivables

DKK 0

Inventories

DKK 0

Total Current Assets

DKK 0

Property Plant Equipment

DKK 0

Total Assets

DKK 0

Payables

DKK 0

Short Term Debt

DKK 0

Long Term Debt

DKK 0

Total Liabilities

DKK 0

Equity

DKK 0

Trend

Cash Flow

(Last Updated 2022-03-31)

Net Income

DKK 0

Depreciation

DKK 0

Change In Working Capital

DKK 0

Cash From Operations

DKK 0

Capital Expenditures

DKK 0

Cash From Investing

DKK 0

Cash From Financing

DKK 0

Net Change In Cash

DKK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.